Sanara MedTech (SMTI) Stock Analysis & AI Equity Report

Medical - Instruments & Supplies USD Explore free reports

Sanara MedTech (SMTI) overview

Sanara MedTech (SMTI) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 103m and operating profit of USD 7.3m; the year-end share price was 23.35 USD and market capitalisation was USD 209m. Sanara MedTech is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Sanara MedTech's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 5.9mFY 2025
Share price23.35 USDFY 2025 year end
RevenueUSD 103mFY 2025
Operating profitUSD 7.3mFY 2025
Net earningsUSD -37.6mFY 2025
Market capitalisationUSD 209mFY 2025 year end

About Sanara MedTech

Sanara MedTech develops and sells medical products for surgical tissue repair and bone fusion. Its products include collagen powder for surgical wound management, a wound irrigation solution, and implants used to support bone growth and fusion. The company markets and distributes these products to surgeons at hospitals and surgical centers, primarily in the United States.

Generate the Sanara MedTech report

Sanara MedTech is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Sanara MedTech and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Sanara MedTech

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.